Nov 7, 2023 Press Releases
PDF Version 124I-evuzamitide shown to be highly accurate for detection of cardiac amyloid across two independent investigator-initiated studies. 124I-evuzamitide detects multiple types of systemic amyloidosis. 124I-evuzamitide may be more sensitive than standard...
Oct 2, 2023 Press Releases
PDF Version AT-01 is a first-in-class pan-amyloid imaging agent capable of detecting diverse types of systemic amyloidosis in multiple organs. AT-01 demonstrated to be highly accurate, with 100% sensitivity for detection of cardiac amyloid, across three independent...
Dec 19, 2022 Press Releases
PDF Version SAN FRANCISCO – December 19, 2022 – Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines to improve the lives of patients with systemic amyloidosis, announced today that the European Commission (EC) and European...